Aimmune Therapeutics, Inc. announced that it has entered into a $170 million loan agreement with an affiliate of KKR. The loan agreement provides Aimmune with an up to $170 million term loan in three tranches. Forty million dollars was funded at close, with $85 million to follow upon FDA approval of AR101 and satisfaction of other customary borrowing conditions, and $45 million at the company’s option in 2020 upon the satisfaction of certain borrowing conditions. The loan can be prepaid at Aimmune’s discretion, at any time, subject to prepayment fees. Further information with respect to the term loan is set out in a Form 8-K filed by Aimmune with the Securities and Exchange Commission on January 4, 2019.